| dc.contributor.author | Sundar, R | |
| dc.contributor.author | Valeri, N | |
| dc.contributor.author | Harrington, KJ | |
| dc.contributor.author | Yap, TA | |
| dc.date.accessioned | 2016-12-12T14:00:58Z | |
| dc.date.issued | 2017-03-01 | |
| dc.identifier.citation | Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, 23 (5), pp. 1123 - 1125 | |
| dc.identifier.issn | 1078-0432 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/326 | |
| dc.identifier.eissn | 1557-3265 | |
| dc.identifier.doi | 10.1158/1078-0432.ccr-16-2399 | |
| dc.description.abstract | The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials. Clin Cancer Res; 23(5); 1123-5. ©2016 AACRSee related article by Calvo et al., p. 1177. | |
| dc.format | Print-Electronic | |
| dc.format.extent | 1123 - 1125 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | AMER ASSOC CANCER RESEARCH | |
| dc.subject | Humans | |
| dc.subject | Neoplasms | |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
| dc.subject | Signal Transduction | |
| dc.subject | Molecular Targeted Therapy | |
| dc.title | Combining Molecularly Targeted Agents: Is More Always Better? | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2016-10-11 | |
| rioxxterms.versionofrecord | 10.1158/1078-0432.ccr-16-2399 | |
| rioxxterms.licenseref.startdate | 2017-03 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Clinical cancer research : an official journal of the American Association for Cancer Research | |
| pubs.issue | 5 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Gastrointestinal Cancer Biology and Genomics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.publication-status | Published | |
| pubs.volume | 23 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Medicine Drug Development Unit (de Bono) | |
| icr.researchteam | Gastrointestinal Cancer Biology and Genomics | |
| icr.researchteam | Targeted Therapy | |
| dc.contributor.icrauthor | Valeri, Nicola | |
| dc.contributor.icrauthor | Harrington, Kevin | |
